MYRIAD GENETICS INC
MYGNdata completeness 88%18 fiscal years on fileMYRIAD GENETICS INC earns about -26% on invested capital, but has diluted owners by 19% over 5 years — worth asking whether the growth reaches owners. The cash-flow models don't apply cleanly here — the ledger says why below.Whether it’s worth owning at today’s price is the last question — and yours to answer, below.
| Figure | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Revenue | $690.6M1 | $678.4M2 | $753.2M3 | $837.6M3 | $824.5M3 |
| Net income | −$27.2M4 | −$112M5 | −$263.3M6 | −$127.3M6 | −$365.9M6 |
| Operating cash flow | $18.6M7 | −$106.3M8 | −$110.9M9 | −$8.7M9 | $1.8M9 |
| Capital expenditure | $18M10 | $45.3M10 | — | — | — |
| Free cash flow (derived) | $600,0007 | −$151.6M8 | — | — | — |
| Total debt | $011 | $012 | $38.5M13 | $39.6M14 | $239.8M14 |
| Cash & equivalents | $257.4M15 | $56.9M16 | $132.1M17 | $102.4M17 | $149.6M17 |
| Diluted shares | 78.0M | 80.6M | 82.8M | 90.6M | 92.6M |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on $39.74 of net worth that earned you −$39.51 last year, against $25.9 of debt.
It earned an average -26% on invested capital over 5 years. Compare that to what it costs to fund the business.
seeing a moat in the numbers →Share count is up 19% over 5 years — owners have been diluted. Worth asking what they got for it.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2021-12-31 · accession 0000899923-24-000018 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2022-12-31 · accession 0000899923-25-000019 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2023-12-31 · accession 0000899923-26-000018 (RevenueFromContractWithCustomerExcludingAssessedTax)
- 10-K · period ending 2021-12-31 · accession 0000899923-24-000018 (NetIncomeLoss)
- 10-K · period ending 2022-12-31 · accession 0000899923-25-000019 (NetIncomeLoss)
- 10-K · period ending 2023-12-31 · accession 0000899923-26-000018 (NetIncomeLoss)
- 10-K · period ending 2021-12-31 · accession 0000899923-24-000018 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2022-12-31 · accession 0000899923-25-000019 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2023-12-31 · accession 0000899923-26-000018 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2021-12-31 · accession 0000899923-23-000011 (PaymentsToAcquireProductiveAssets)
- 10-K · period ending 2021-12-31 · accession 0000899923-22-000033 (LongTermDebtNoncurrent)
- 10-K · period ending 2022-12-31 · accession 0000899923-24-000018 (LongTermDebtNoncurrent)
- 10-K · period ending 2023-12-31 · accession 0000899923-25-000019 (LongTermDebtNoncurrent)
- 10-K · period ending 2024-12-31 · accession 0000899923-26-000018 (LongTermDebtNoncurrent)
- 10-K · period ending 2021-12-31 · accession 0000899923-24-000018 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2022-12-31 · accession 0000899923-25-000019 (CashAndCashEquivalentsAtCarryingValue)
- 10-K · period ending 2023-12-31 · accession 0000899923-26-000018 (CashAndCashEquivalentsAtCarryingValue)